The company said the patents relate to selective 5-HT 6 and 5HT 4 compounds, which are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” said Venkat Jasti, CEO of Suven.
A month ago, the company reported getting more patents in India and South Korea for its drugs designed for treating neurodegenerative diseases.
Suven Life Sciences is biopharmaceutical company and focuses on discovering, developing and commercializing new drugs aimed at nervous disorders.
Suven has 4 clinical stage compounds. The most advanced is SUVN-502, which is currently in Phase 2 clinical trial. It also has SUVN-G3031, which is ready for Phase 2 trial and SUVN-D4010, which has completed Phase 1.
The latest, SUVN-911, has started Phase 1 clinical trial.
It also has nine drug candidates currently in various stages of pre-clinical development. These are targeted at ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.